A Nature Communications study provides real-world comparative safety evidence for second-line antihyperglycemic agents in elderly patients with type 2 diabetes, led by Kim, Bu, Blacketer, and colleagues. The paper frames its findings around risks observed in routine care rather than controlled trial settings. For geriatric diabetes management, safety tradeoffs are often decisive, particularly for drug classes that can introduce hypoglycemia, renal dosing constraints, or other age-related vulnerabilities. This new evidence is aimed at improving medication selection for older adults when treatment escalates beyond first-line therapy. The work adds to an evidence base that is still uneven across older age groups, supporting more granular prescribing decisions based on real-world experience.